Sharon Smith

Bulevirtide (Hepcludex; Gilead Sciences, Inc.) is the first FDA-approved treatment for chronic hepatitis delta virus infection. Medscape Medical News source https://www.medscape.com/viewarticle/fda-approves-bulevirtide-hepatitis-delta-virus-2026a1000h3x?src=rss

Most available drugs are effective for symptom control and structural protection, but they’re not perfect and new agents are being investigated to help close the treatment gap. Medscape Medical News source https://www.medscape.com/viewarticle/whats-axial-spondyloarthritis-treatment-pipeline-2026a1000gyu?src=rss

Advice on when and how to switch or stack treatments can help in cases of an incomplete or waning response. Medscape Medical News source https://www.medscape.com/viewarticle/expert-guidance-switching-stacking-systemic-therapies-2026a1000gyp?src=rss

Semaglutide and tirzepatide use is rising among patients with rheumatic and musculoskeletal diseases and is linked to meaningful 1-year weight loss, especially in tirzepatide users. Medscape Medical News source https://www.medscape.com/viewarticle/glp-1s-tied-weight-loss-real-world-rheumatologic-care-2026a1000gmt?src=rss

A phase 3 trial explores whether adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improves overall survival in patients with gastric cancer and peritoneal metastasis. Medscape Medical News source https://www.medscape.com/viewarticle/can-intraperitoneal-paclitaxel-improve-survival-gastric-2026a1000gmg?src=rss

The same hurdles facing physicians slow treatment for nurse practitioners’ patients, and the impact on care continues. Medscape Medical News source https://www.medscape.com/viewarticle/how-nps-are-navigating-prior-authorization-coverage-barriers-2026a1000gm0?src=rss